Header

UZH-Logo

Maintenance Infos

Browse by Creators

Navigate back| Up a level
Export as
Number of items: 13.

Creutzig, U; Dworzak, M N; Zimmermann, M; Bourquin, J-P; Gruhn, B; Fleischhack, G; Graf, N; Klingebiel, T; Kremens, B; Lehrnbecher, T; von Neuhoff, C; Stackelberg, A V; Starý, J; Reinhardt, D (2015). Additional treatment with 2-Chloro-2-Deoxyadenosine during consolidation in children with high-risk acute myeloid leukemia does not improve survival. Leukemia, 29(11):2260-2263.

Eckert, C; Hagedorn, N; Sramkova, L; Mann, G; Panzer-Grümayer, R; Peters, C; Bourquin, J-P; Klingebiel, T; Borkhardt, A; Cario, G; Alten, J; Escherich, G; Astrahantseff, K; Seeger, K; Henze, G; von Stackelberg, A (2015). Monitoring minimal residual disease in children with high-risk relapses of acute lymphoblastic leukemia: prognostic relevance of early and late assessment. Leukemia, 29(8):1648-1655.

Creutzig, U; Dworzak, M; Zimmermann, M; Bourquin, J-P; Gruhn, B; Fleischhack, G; Graf, N; Klingebiel, T; Kremens, B; Lehrnbecher, T; von Neuhoff, C; von Stackelberg, A; Stray, J; Reinhardt, D (2015). Randomised Introduction of 2-CDA as Intensification during Consolidation for Children with High-risk AML--results from Study AML-BFM 2004. Klinische Pädiatrie, 227(3):116-122.

Burger, M C; Brucker, D P; Baumgarten, P; Ronellenfitsch, M W; Wanka, C; Hasselblatt, M; Eccles, M R; Klingebiel, T; Weller, M; Rieger, J; Mittelbronn, M; Steinbach, J P (2012). PAX2 is an antiapoptotic molecule with deregulated expression in medulloblastoma. International Journal of Oncology, 41(1):235-241.

Paulides, M; Stöhr, W; Laws, H J; Graf, N; Lakomek, M; Berthold, F; Schmitt, K; Niggli, F; Jürgens, H; Bielack, S; Koscielniak, E; Klingebiel, T; Langer, T (2011). Antibody levels against tetanus and diphtheria after polychemotherapy for childhood sarcoma: a report from the Late Effects Surveillance System. Vaccine, 29(8):1565-1568.

Schrappe, M; Valsecchi, M G; Bartram, C R; Schrauder, A; Panzer-Grümayer, R; Möricke, A; Parasole, R; Zimmermann, M; Dworzak, M; Buldini, B; Reiter, A; Basso, G; Klingebiel, T; Messina, C; Ratei, R; Cazzaniga, G; Koehler, R; Locatelli, F; Schäfer, B W; Aricò, M; Welte, K; van Dongen, J J M; Gadner, H; Biondi, A; Conter, V (2011). Late MRD response determines relapse risk overall and in subsets of childhood T-cell ALL: results of the AIEOP-BFM-ALL 2000 study. Blood, 118(8):2077-2084.

Paulides, M; Stöhr, W; Laws, H J; Graf, N; Lakomek, M; Berthold, F; Schmitt, K; Niggli, F; Jürgens, H; Bielack, S; Koscielniak, E; Klingebiel, T; Langer, T (2010). Immunity against tetanus and diphtheria after childhood sarcoma treatment. Klinische Pädiatrie, 222(3):196.

Tallen, G; Ratei, R; Mann, G; Kaspers, G; Niggli, F; Karachunsky, A; Ebell, W; Escherich, G; Schrappe, M; Klingebiel, T; Fengler, R; Henze, G; von Stackelberg, A (2010). Long-term outcome in children with relapsed acute lymphoblastic leukemia after time-point and site-of-relapse stratification and intensified short-course multidrug chemotherapy: results of trial ALL-REZ BFM 90. Journal of Clinical Oncology, 28(14):2339-2347.

Möricke, A; Zimmermann, M; Reiter, A; Henze, G; Schrauder, A; Gadner, H; Ludwig, W D; Ritter, J; Harbott, J; Mann, G; Klingebiel, T; Zintl, F; Niemeyer, C; Kremens, B; Niggli, F; Niethammer, D; Welte, K; Stanulla, M; Odenwald, E; Riehm, H; Schrappe, M (2010). Long-term results of five consecutive trials in childhood acute lymphoblastic leukemia performed by the ALL-BFM study group from 1981 to 2000. Leukemia, 24(2):265-284.

Kager, L; Zoubek, A; Dominkus, M; Lang, S; Bodmer, N; Jundt, G; Klingebiel, T; Jürgens, H; Gadner, H; Bielack, S (2010). Osteosarcoma in very young children: experience of the Cooperative Osteosarcoma Study Group. Cancer, 116(22):5316-5324.

Meyer, C; Kowarz, E; Hofmann, J; Renneville, A; Zuna, J; Trka, J; Ben Abdelali, R; Macintyre, E; De Braekeleer, E; De Braekeleer, M; Delabesse, E; de Oliveira, M P; Cavé, H; Clappier, E; van Dongen, J J M; Balgobind, B V; van den Heuvel-Eibrink, M M; Beverloo, H B; Panzer-Grümayer, R; Teigler-Schlegel, A; Harbott, J; Kjeldsen, E; Schnittger, S; Koehl, U; Gruhn, B; Heidenreich, O; Chan, L C; Yip, S F; Krzywinski, M; Eckert, C; Möricke, A; Schrappe, M; Alonso, C N; Schäfer, B W; Krauter, J; Lee, D A; Zur Stadt, U; Te Kronnie, G; Sutton, R; Izraeli, S; Trakhtenbrot, L; Lo Nigro, L; Tsaur, G; Fechina, L; Szczepanski, T; Strehl, S; Ilencikova, D; Molkentin, M; Burmeister, T; Dingermann, T; Klingebiel, T; Marschalek, R (2009). New insights to the MLL recombinome of acute leukemias. Leukemia, 23(8):1490-1499.

Dantonello, T M; Int-Veen, C; Winkler, P; Leuschner, I; Schuck, A; Schmidt, B F; Lochbuehler, H; Kirsch, S; Hallmen, E; Veit-Friedrich, I; Bielack, S S; Niggli, F; Kazanowska, B; Ladenstein, R; Wiebe, T; Klingebiel, T; Treuner, J; Koscielniak, E (2008). Initial patient characteristics can predict pattern and risk of relapse in localized rhabdomyosarcoma. Journal of Clinical Oncology, 26(3):406-413.

Möricke, A; Reiter, A; Zimmermann, M; Gadner, H; Stanulla, M; Dördelmann, N; Löning, L; Beier, R; Ludwig, W D; Ratei, R; Harbott, J; Boos, H; Mann, G; Niggli, F; Feldges, A; Henze, G; Welte, K; Beck, J D; Klingebiel, T; Niemeyer, C; Zintl, F; Bode, U; Urban, C; Wehinger, H; Niethammer, D; Riehm, H; Schrappe, M (2008). Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95. Blood, 111(9):4477-4489.

This list was generated on Mon Nov 20 13:05:03 2017 CET.